Purpose: To assess the sensitivity of various EPID dosimetry alert indicators to patient-related variations and to determine alert threshold values that ensure excellent error detectability. Methods: Our virtual dose reconstruction method uses in air EPID measurements to calculate virtual 3D dose distributions within a CT data set. Patient errors are introduced by transforming the plan-CT into an error-CT data set. Virtual patient dose distributions reconstructed using the plan-CT and the error-CT data set are compared to the planned dose distributions by c(3%/3 mm) and DVH analysis using seven indicators: DD ISOC , c-mean, near c-max, c-pass rate, DPTV D2 , DPTV D50, and DPTV D98 . Translation and rotation patient setup errors and uniform contour changes are studied for 104 VMAT plans of 4 treatment sites. Lung expansions and contractions to simulate changes in lung density are considered for 26 IMRT lung plans. A ROC curve is generated for each combination of error and indicator. For each ROC curve, the AUC value and the optimal alert threshold value of the indicator are determined. Results: AUC values for c-indicators and DPTV D2 are consistently higher than for DD ISOC and DPTV D98 . For VMAT plans, error detectability to patient position shifts is worse for pelvic treatments and best for head-and-neck and brain plans. Excellent detectability is observed for 5 mm translations in head-and-neck plans (AUC = 0.94) and for 4°rotations in brain plans (AUC = 0.89). All sites but prostate show good-to-excellent detectability (AUC > 0.8) for 10 mm translations and 8°r otations and excellent detectability (AUC > 0.9) for AE6 mm patient contour changes. For head-andneck, excellent detectability is obtained with c-mean and c-pass rate threshold values of around 0.63 and 83%, respectively. For brain and rectum, these threshold values are 0.53 and 90%, respectively. In IMRT lung plans, expansions of 3 mm and contractions of 6 mm are detected (AUC > 0.8).
INTRODUCTION
Although initially developed to improve the accuracy of patient setup, electronic portal imaging devices (EPIDs) show also useful dosimetric characteristics [1] [2] [3] [4] [5] [6] [7] [8] and are now commonly used for pretreatment and in vivo dosimetric verification of both IMRT [9] [10] [11] [12] [13] [14] [15] and VMAT [16] [17] [18] [19] [20] treatments. At our institute, we employ an EPID transit dosimetry method to verify all treatments automatically. 12, 16, 21, 22 In vivo EPID-based patient 3D dose distributions are compared with planned dose distributions by performing c-analysis and results are presented for a set of indicators. For each indicator, an alert threshold value is chosen and the system acts as a binary classifier where treatments are classified either as positives (alerted) or negatives (not alerted). The system classifies a no-error delivery either correctly as a true negative (TN) or incorrectly as a false positive (FP). Similarly, an error delivery is classified either correctly as a true positive (TP) or incorrectly as a false negative (FN). Patient-specific pretreatment QA verifies that the TPS dose calculation is accurate and that the treatment is deliverable on the machine as planned. In vivo dose verification presents additional challenges since the dose delivered to the patient during treatment is affected by patient setup variations and patient anatomical changes. An in vivo dose verification system should be sensitive to all possible causes of dose deviations and classify them as positives (TPs), particularly if they are relevant for treatment outcome. Similarly, treatments that are correctly delivered should be classified as negatives (TNs) . The efficiency of an in vivo method is limited by the accuracy of the dose reconstruction algorithm and therefore sometimes treatments are incorrectly classified. False positives (FPs) lead to unnecessary extra inspection work while FNs are more dangerous, since delivery errors are not being detected by the system. The accuracy of an algorithm is usually technique and treatment site dependent. In a recent overview of our clinical experience, 23 we indicated that about 30% of our treatments are flagged as positives and require inspection. Although machine and/or transfer errors still may occur, 24 these are rare incidents and the majority of these positives can be explained either by limitations in the accuracy of our dose reconstruction model or by observed patient anatomical changes (after visual inspection of IGRT data).
IMRT and VMAT QA systems for pretreatment and in vivo verification are traditionally commissioned without knowledge of their sensitivity to clinically relevant delivery errors, and QA passing criteria are normally based exclusively on their tolerance to FPs. The final performance of an error classifier system should be, however, evaluated by programmatically assessing its sensitivity and specificity, that is, the TP rate and the TN rate, respectively. Several sensitivity studies of pretreatment QA measurement devices to TPS beam model errors and to machine-related errors can already be found in the literature. [25] [26] [27] [28] [29] [30] [31] These studies indicate that QA devices are different in their ability to detect errors and that results are specific to the delivery technique employed and to the disease treatment site. Sensitivity studies of in vivo EPID dosimetry systems are very rare in the literature. Bedford et al. 32 investigated recently the performance of forward-and back-projection in vivo EPID dosimetry methods by delivering 13 VMAT prostate plans with deliberately introduced errors to a slab phantom. Patient-related anatomical changes were introduced by placing air gaps in a water-equivalent phantom to simulate rectal fillings. The results obtained with the unmodified phantom were used as baseline. The main drawback of this approach is that the introduction of errors simulating in vivo patient-related variations requires the use of anthropomorphic phantoms in order to simulate the attenuation properties of a human body for each specific site. Recently, we performed a study of the effectiveness of our EPIDbased 3D transit dosimetry system in detecting deliberately introduced errors by irradiating an Alderson phantom, using four VMAT plans (one prostate, two head-and-neck and one lung case) in which delivery, thickness and setup errors were introduced. 33 The small number of cases and error types are, however, a limitation of such a type of study. Bojechko and Ford 34 already studied the sensitivity of our in vivo transit dosimetry method for four types of treatment variations using 70 IMRT fields of 9 IMRT plans delivered to five treatment sites. They assessed the sensitivity of the method by employing a receiver operating characteristic (ROC) analysis. In their work, patient-related variations such as patient shifts or expansion and contraction of patient's body contours were simulated in the TPS. For the ROC analysis, in vivo EPID data was compared with both unmodified and modified TPS dose distributions. A limitation of this approach is that the collected in vivo EPID data contains patient-related variations which already have a nonquantified effect on the results of the comparison with the unmodified plans. The authors concluded that patient position changes are not reliably detected by in vivo EPID dosimetry for the soft tissue abdominal sites used in their analysis and suggested to expand the study to other sites such as head-and-neck where the system should be more sensitive to these variations. Also, they highlighted the need to perform similar studies for VMAT treatments.
This study presents a framework to analyze the sensitivity and specificity of 3D EPID transit dosimetry to patientrelated variations. The method requires neither phantom measurements nor the use of a TPS for the introduction of errors. In addition, it can easily be automated which makes it suitable for large-scale studies. Per treatment plan, the method involves the acquisition of in air EPID measurements while patient-related variations are simulated by conveniently transforming the original CT data set in our virtual dose reconstruction engine. 35 The introduced variations include translations and rotations of patient position and contour changes for 104 VMAT plans (four treatment sites) and density changes for 26 IMRT lung plans. Results are analyzed for all plans as well as per site. Also innovative is the use of seven alert indicators: dose difference at the isocenter (DD ISOC ), mean value of the c-distribution (c-mean), 99th percentile of the c-distribution (near c-max), percentage of voxels with c < 1 (c-pass rate), difference in near maximum dose to the PTV (DPTV D2 ), difference in median dose to the PTV (DPTV D50 ) and difference in near minimum dose to the PTV (DPTV D98 ). The ability of our EPID transit dosimetry to detect each introduced patient variation is evaluated individually for all indicators. The magnitude of the errors and the set of alert threshold values for which the method can ensure an excellent detectability is also determined.
MATERIALS AND METHODS

2.A. EPID measurements and equipment
Measurements are performed on Precise linear accelerators (Elekta, Crawley, UK) equipped with a standard MLCi (1 cm leaf width) and on VersaHD linear accelerators (Elekta, Crawley, UK) equipped with an Agility MLC (5 mm leaf width). All linacs are equipped with a PerkinElmer RID 1680 AL5/Elekta iViewGT amorphous silicon EPID which is situated at a 160 cm distance from the linac focus with a sensitive area of 41 9 41 cm 2 . For IMRT verification, our in-house acquisition software averages the total signal of all EPID frames between beam-on and beam-off into one accumulated portal image, which is stored with the number of frames in the image header. For VMAT verification, cine-mode image acquisition is used and separate EPID frames are continuously being acquired during delivery. Each recorded frame is associated with a gantry angle. Treatment plans in this study were generated with Pinnacle V9.10 (Philips Medical Systems, Eindhoven, The Netherlands). 
Full details regarding Eq. (1) can be found in the original design of the algorithm by Wendling et al. 12, 21 The algorithm requires also the primary dose transmission at the EPID level which is given by:
The in air primary portal dose distribution can be calculated from the pixel values PV EPID;inair ij of EPID images recorded without the patient in the beam following also Eq. (1), but this time without the corrections for the couch attenuation and the patient scatter. The primary dose transmission at the EPID level can, however, also be calculated from the CT data set using the radiological thickness of the patient t radiol ij , the linear attenuation coefficient of water for a specific beam energy l and the beam hardening coefficient r as shown in Eq. (3) 37 :
The concept of calculating the primary dose transmission behind a patient or phantom was clinically introduced when our model was adapted for its use for VMAT verification. 16 The numerical values for l and r are determined during the commissioning process of the portal dosimetry system by fitting Eqs. (3) to (2) for a set of fields measured with the EPID behind phantoms of different thicknesses. As result, for a CT data set representing any given patient anatomy, we can determine the "virtual" patient primary portal dose distribution by:
If we use the planned CT data set in Eq. (4), the virtualplan primary portal dose distribution is given by:
Virtual-plan primary portal dose distributions predict the transit primary portal dose distributions that we would measure behind a patient without changes in anatomy. Patient dose reconstructions calculated with virtual-plan primary portal dose distributions are suitable for patient-specific pretreatment QA since Pr EPID;in air ij contains information about the dose to be delivered to the patient, including machine and/or planning errors. This methodology has been validated against dose measurements made with an ionization chamber and with the OCTAVIUS 4D system, as well as against TPS patient data, 35 and is since 2017 our standard methodology for pretreatment verification in our clinic.
During treatment delivery, patient-related errors have an effect on the final delivered dose to the patient and, therefore on the in vivo primary portal dose distribution that is measured behind the patient for in vivo dose verification using Eq. (1). The challenge of using real patient data for a sensitivity study resides in programmatically and accurately determining the nature and magnitude of the patient-related error that applies to each in vivo measurement. In this study, we circumvent this problem by modifying the virtual dose engine algorithm to conveniently introduce patient-related errors. The original CT data set of the patient is transformed first into a CT-error data set that contains a given patient variation, and then, we use this CT-error data set to predict a virtualerror primary portal dose distribution by:
Similarly to Eq. (5), virtual-error primary portal dose distributions predict the transit primary portal dose distributions that we would measure behind a patient with the introduced error. Note that in our current clinical practice where no CBCT data is used, the back-projection of the in vivo primary portal dose distribution Pr EPID;transit ij is performed using the original CT-plan data set. In order to mimic this clinical practice, the back-projection of the virtual-error primary portal dose distribution Pr EPID;virtualÀerror ij in this study is also performed using the original CT-plan data set (instead of the CT-error data set). Because the same algorithm is used, virtual-error patient dose distributions are conveniently used as synthetic in vivo patient data in this study.
2.C. Plan selection
The population of plans includes a representative set of treatment sites. We separate plans per site because the effect of patient-related variations on the EPID-reconstructed dose distributions is expected to differ per site. For this study, 130 treatment plans are randomly selected among our clinical plans: 27 VMAT prostate, 24 VMAT head-and-neck, 29 VMAT brain, 24 VMAT rectum, and 26 IMRT lung. In air EPID measurements are acquired for each treatment.
2.D. Introduction of patient variations
For each VMAT plan, the following variations are considered:
• Translation shifts in patient position by transforming the original CT data set with translations of 5, 10, 15, and 20 mm in the three cardinal directions, denoted by T5, T10, T15, and T20, respectively.
• Rotation shifts in patient position by transforming the original CT data with 4°, 8°, 12°, and 16°rotations along the cranio-caudal and left-right axes, denoted by R4, R8, R12, and R20, respectively.
• Patient contour changes by uniformly expanding and contracting the contour of the patient of the original CT data set by AE3 and AE6 mm, denoted by CAE3 and CAE6, respectively. The HU value is constant in the expanded volume and equal to the mean value of the original CT data set. The HU value equals to that of air in the contracted volume.
A predominant cause for adaptation in lung cancer patients is changes in density due to atelectasis or pleural effusion changes. [38] [39] [40] For each IMRT lung plan, changes in lung density are simulated by uniformly expanding and contracting the lung contours of the original CT data set by AE3, AE6, and À9 mm, denoted by LCAE3, LCAE6, and LCÀ9, respectively. The HU value is constant in the expanded lung volume and equal to the mean lung value in the original CT data set. The HU value is also constant in the contracted lung volume and equal to that of water.
2.E. Dose verification
The in air EPID measurements are combined with the CTplan and CT-error data sets to automatically reconstruct 130 virtual-plan and 1378 virtual-error patient 3D dose distributions. For dose verifications of sites involving (large) tissue heterogeneities, for example, lung, the in aqua vivo approach is always used. 41 Virtual patient 3D dose distributions are compared to the planned dose distributions by c-analysis 42, 43 and DVH analysis using seven indicators: DD ISOC , c-mean, near c-max, c-pass rate, DPTV D2 , DPTV D50 , and DPTV D98 . Note that D expresses the dose difference between EPID and plan as (EPID-plan)/plan. c-evaluation is performed using as c-criterion a dose difference of 3% of the maximum dose and a distance-to-agreement of 3 mm. c-statistics are calculated within the volume surrounded by the 50% isodose surface. As an example, Fig. 1 shows the method being applied to study the effect of increasing rotation shifts in patient position on the dose verification results of a VMAT rectum treatment.
2.D. ROC analysis
A receiver operating characteristic (ROC) curve is a graphical plot which illustrates the performance of a binary classifier system as the indicator threshold value is varied. 28 Typically, an area under the curve (AUC) of 0.5 suggests no discrimination, 0.7 to 0.8 is considered acceptable, 0.8 to 0.9 is considered good, and more than 0.9 is considered excellent. 44 In this study, ROC curves are generated for each combination of error and alert indicator yielding a total of 84 global ROC curves and 371 site-specific ROC curves. Virtual-plan and virtual-error dose verification results are used as no-error and error ROC populations, respectively. For each ROC curve, we determine its AUC value and the optimal value range for the alert indicator. Table I presents the average dose verification results of the 130 virtual-plan patient dose reconstructions employed in this study. Results are presented for seven indicators and are consistent with previous pretreatment studies. 35 For the sake of this work, we assume that the plans are delivered in the absence of machine systematic or random variations. Over the period in which the measurements were performed, the average daily output correction of the accelerators was 0.0% AE0.4%(1 SD) which is considered small enough to be ignored.
RESULTS
3.A. Plan verification without patient variations
3.B. Detectability of variations in patient position and in patient contour
AUC values of 84 VMAT ROC curves are shown in Table II . The results indicate good detectability (AUC > 0.8) for translation shifts of 10 mm, rotation shifts of 8°and uniform contour expansions and/or contractions of 6 mm. AUC values for c-indicators and DPTV D2 show overall the best detectability. c-indicators and DPTV D2 perform similarly for translation variations whereas c-pass rate and DPTV D2 are the best indicators to detect rotation variations and contour changes, respectively. DPTV D50 shows only good detectability to the largest translation and rotation variations. DD ISOC does not perform as well as DPTV D50 and shows only good detectability for contour changes of +6 mm. DPTV D98 performs worst with the highest AUC value of 0.77. Figure 2 illustrates the performance of c-pass rate, %DPTV D50 and % DD ISOC by displaying their ROC curves for the twelve introduced patient variations. Figure 3(a) illustrates the sensitivity of c-pass rate to the introduced patient variations by displaying box plots of the dose verification results. The minimum and median values of the no-error distribution are 85.7% and 98.1%, respectively. Note how this median value is slightly higher than the average value presented in Table I . Median values decrease as the severity of the translation and rotation errors increases to 94.7%-89.8%-80.6%-64.9% and Fig. 3 (b) displays boxplots of %DPTV D50 results. Note how, on average, the increase in detected PTV D50 values in contour contractions is similar to the decrease in contour expansions. As can be seen, the sensitivity is highest for the introduced rotations errors, and notably in head-and-neck and brain plans. Figure 4 displays site-specific c-pass rate ROC curves for the twelve introduced patient variations. As can be seen, error detectability to patient position shifts is worse for pelvic treatments and best for head-and-neck or brain plans. Variations in patient position for pelvic treatments have little effect on transmission and hence these variations go easily undetected at EPID level. Head-and-neck shows excellent detectability already for translations of 5 mm. All sites but prostate show good-to-excellent detectability for translations of 10 mm. Head-and-neck and brain show nearly excellent detectability for rotations of 4°and all sites except prostate show goodto-excellent detectability for rotations of 8°. In patient contour changes, all sites show good-to-excellent detectability for changes of AE6 mm. Prostate is again the site with the poorest performance. In patient contour changes, the full beam is extra attenuated in contour expansions which causes a lower dose to be delivered to the target volume. The effect is opposite in contour contractions. In contractions of 3 mm, for instance, the relative loss in patient volume is smaller in pelvic treatments (around 6%) than in head-and-neck or brain treatments (around 11%). These different patient volume losses have a direct effect on the relative changes in transmission and hence on the observed differences in performance. Table III presents the set of site-specific threshold alert values capable of ensuring an excellent detectability. Data are presented only for c-indicators. The ROC curve of the smallest error with AUC > 0.9 is chosen to calculate the optimal alert value for each error type. The optimal value of the indicator is defined by the point closest to (0.0, 1.0) in the ROC space. In case of an optimal range of values, the middle value within the range is presented for simplicity. Alert threshold values vary per treatment site and also (albeit less) per patient variation type. Between brackets, the specificity and sensitivity that correspond to the indicator values are included. Note that a perfect classification (100/100) is found only for head-and-neck with T15, R16, and CÀ6 variations and for rectum with T20, R16, and CÀ6 variations. Since the presented framework allows us to obtain results for different levels of error detectability, Table IV presents also the set of c-pass rate threshold values that ensure good detectability (AUC > 0.8). These results are examined further in the Section 4.
3.C. Site-specific detectability of variations in patient position and in patient contour
3.D. Detectability of IMRT lung density changes
AUC values are higher in lung expansions than in lung contractions, as can be seen from the results displayed in Table V . For AE3 mm variations, the extended and contracted lung volumes are on average 20% larger and 16% smaller than the original volume, respectively. This originates in an average decrease of lung density in the extended lung volume of 28% and an average increase of 19% in the original volume after the lung is contracted. As a result, the IMRT beams are more strongly affected by expansions than by contractions of the same size. This is corroborated with the boxplots presented in Fig. 5 , where an average %DPTV D50 value increase relative to the no-error situation of 1.9% is observed for a 3 mm expansion whereas the average decrease is 0.9% for a 3 mm contraction. Note also how the sensitivity of this indicator to contractions of 6 mm is similar to expansions of 3 mm (À2.2% vs À1.9%). However, this does not translate to similar AUC values for these variations due to the systematic overdose present in the no-error situation (median value of +0.7%) which artificially boost the sensitivity of the method to variations that originate a decrease in transmission such as is the case with the overall decrease in lung density in the lung extensions of this example. For expansions of 3 mm, excellent detectability is achieved with alert threshold values for c-mean and c-pass rate of 0.41 (81/92) and 96% (85/92), respectively. For contractions of 9 mm, these values are 0.48 (96/88) and 95% (88/88), respectively. A perfect classification (100/100) can be achieved for lung volume expansions of 6 mm using values of 0.51 and 90%, respectively.
DISCUSSION
In this study, we have introduced an innovative and effective method to assess site-specific alert criteria in the detection of patient variations with our in vivo 3D EPID transit dosimetry solution. The method presents unique advantages. First of all, both the introduction of variations and the generation of ROC curves is an automated process which makes it suitable for large-scale studies. Also, the effect of changes in the reconstruction algorithm or in the comparison metrics can easily be re-evaluated. Secondly, the only measurements needed are in air EPID measurements, eliminating thus the need for phantom positioning and replanning. Finally, the method can easily be adapted to study any other 
an excellent detectability is also indicated. The detected specificity and the sensitivity are finally displayed between brackets for completeness. A cross indicates that excellent detectability could not be found with the errors explored.
c-mean c-pass rate % Near c-max patient-specific variation for as long as the original CT data set can be transformed into a CT-error data set that conveniently represents the variation of interest.
The results presented in Tables II and V indicate that error detectability differs per indicator. We employ clinically a multiindicator approach and treatments are currently alerted using a combination of %DD ISOC and c-indicators. This study proves that %DD ISOC does not perform as well as other indicators, illustrating the need for in vivo dosimetry in 2D or 3D. As an alternative for an indicator to score on dose differences, the use of %DPTV D2 is encouraged. At our institute, we currently use different sets of in vivo alert criteria. 23 Most treatment sites use the strictest set. Head-and-neck, rectum, and gynecology use a less strict set and, finally, breast uses the most indulgent set. The alert threshold values that we currently use were originally based on pretreatment results using phantom irradiations and were dynamically adapted with growing clinical experience. This study is our first attempt to programmatically determine alert threshold values. Assuming that the TPS calculated the dose distributions correctly and that the machines delivered the plans perfectly, the average virtual-plan dose verification results presented in Table I for the no-error distributions represent the expected accuracy of our EPID transit dosimetry methodology in the absence of patient-related variations. Keeping this accuracy high is essential for error detectability and should be evaluated upon any change in the reconstruction algorithm. In this study, the dosimetric effect of patient variations on our algorithm is evaluated by calculating virtual-error patient dose distributions that can be used as synthetic in vivo data. The example of Fig. 1 and the boxplots of Figs. 3 and 5 illustrate how these dose verification results worsen as the magnitude of the introduced patient-related variation increases. The final error detectability of the system in practice may be slightly different in specific cases of suboptimal modeling for the dose-response model of the EPID behind the patient or for the patient scatter reaching the EPID in Eq. (1) . The impact of these in vivo limitations of the model could be estimated by comparing the results of irradiating the same plans of this study to an anthropomorphic phantom with those presented in Table I .
The results of this study have an immediate clinical impact because they quantify with numbers the ability of EPID transit dosimetry to detect patient-related errors of different magnitudes for specific sites. For instance, in Table III we determine the magnitude of the variations for which our system is capable of acting as an excellent classifier system. We aim at excellent detectability because ideally we wish to keep the number of FPs and FNs as low as possible. In clinical practice, however, we could decide to use another set of alert threshold values in order to be able to detect smaller errors that those presented in Table III . As an example, Table IV displays c-pass rate alert threshold values that ensure good detectability. Note how in this case, smaller errors can be then detected but at the cost of a lower sensitivity and specificity. Note also that clinically useful criteria aim at the detection of all kind of errors (not only patient-related), and may therefore deviate from the ones presented in this study.
The results of Tables III and IV highlight potential clinical situations in which in vivo EPID transit dosimetry cannot be readily used as a reliable classifier system if we understand as a positive any situation that hinders treatment outcome, or in other words, they emphasize the need for IGRT techniques to handle the challenge of daily patient variations. In our in vivo EPID transit dosimetry method, a treatment is alerted (positive) only when the dose has not been delivered as intended in the spatial domain. Although the discussion applies to all treatment sites, let us consider a prostate treatment with horizontal translation and/or left-right rotation patient position shifts. If the changes in patient density are small, in vivo 3D EPID dosimetry will not alert this treatment because the dose is correctly delivered to where it was intended, that is, the PTV. But if this undetected displacement is clinically relevant, we have a case of a false negative. As reported in Table IV , this may happen already for <2 cm translations and/or <10°rotations. In these cases, performing a dosimetric verification of the treatment with 3D EPID transit dosimetry may be insufficient and more complex techniques such as deformable dose accumulation are required to quantify the dose delivered to the CTV and to the normal tissue volumes over the course of the treatment.
As has been said, the results of a sensitivity study are also specific to the dose reconstruction algorithm employed. In the previous study that Bojechko and Ford 34 performed with our algorithm, they used data from 70 fields of 9 IMRT plans and found c-pass rate AUC values of 0.67-0.70 for contour changes of 5 mm and 0.88 for changes of 10 mm. In our study, we analyze data from 104 VMAT plans and find AUC values of 0.64-0.71 and 0.80-0.88 for contour changes of 3 and 6 mm, respectively, which indicates a higher sensitivity to changes in patient contour. Apart from the discrepancies that can arise due to the population of plans and/or the approach taken, there is a significant difference in the way our algorithm operates for IMRT and VMAT. In IMRT, the primary dose transmission at EPID level is measured as the ratio of the primary portal dose distributions of two accumulated EPID images, one measured behind the patient and another without the patient in the beam, see Eq. (2). In VMAT, however, an accurate determination of the transmission of individual frames from arcs measured behind the patient and without the patient in the beam is impossible because fluctuations in the delivery are not synchronized with frame acquisition. In our clinical practice, the primary dose transmission is recalculated from CT data for each frame, see Eq. (3). Dose reconstructions using CT-based calculated transmission compared with using EPID-based measurements are more sensitive to detecting changes in the thickness of the patient. 37 This explains the differences in the obtained results and illustrates their dependence to the dose reconstruction algorithm employed. If CBCT data sets are used to calculate the daily primary dose transmission in our VMAT back-projection algorithm, then the results of this study have to be re-evaluated.
In addition, EPID transit dosimetry has limitations in itself. Patient-related variations can only be detected if they generate a change in the transmitted signal at the EPID level. Overall changes in patient density such as the contour changes considered in this study can be readily detected. But this may not apply to cases with nonuniform local density changes. For instance, situations where an increase in patient density upstream of the tumor volume may be compensated by an equivalent decrease downstream can be wrongly classified as a negative by EPID transit dosimetry. Future work includes an assessment of the accuracy of the clinical deviations detected by our EPID transit back-projection algorithm.
Finally, it is worth noting that the goal of in vivo EPID transit dosimetry is not per se the accurate determination of the actual delivered dose to the patient, but the ability to catch clinically relevant errors at the end of the radiotherapy chain. In our opinion, specificity-sensitivity studies such as this one are essential to assess the potential for error detectability of any in vivo EPID transit dosimetry solution, either forwardor back-projection based.
CONCLUSION
By combining virtual dose reconstructions with synthetic patient data, we developed a framework to assess the sensitivity of our 3D EPID transit dosimetry method to patientrelated variations. The detectability of each introduced error is specific to the treatment site and indicator used. Optimal alert criteria can be determined to ensure excellent detectability for each combination of error type and indicator. The alert threshold values and the magnitude of the error that can be detected are site-specific. In situations where the minimum error that can be detected is larger than the clinically desirable action level, EPID transit dosimetry must be used in combination with IGRT procedures to ensure correct patient positioning and early detection of anatomy variations.
